Dyadic International, Inc. is a global biotechnology company. The Company is focused on developing and licensing the C1 platform for use in human and animal pharmaceutical applications across the world. The Company has developed a method for producing commercial quantities of enzymes and other proteins, which it uses to develop and produce some of its own industrial enzymes, as well as licensing this technology to third parties. This technology is based on the Myceliopthora thermophila fungus, which the Company named C1. The C1 technology is a fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.